Health
Biogen Beats Estimates as Alzheimer’s Drug Gains Momentum
Alzheimer's treatment Leqembi was approved in 2023.
Photographer: Hannah Yoon/The Washington Post/Getty ImagesBiogen Inc.’s first-quarter sales and profit beat expectations, a sign that the company’s Alzheimer’s drug and cost cuts are helping offset pressure on its multiple sclerosis franchise.
Revenue rose 2% to $2.5 billion and adjusted earnings grew 18% to $3.57 a share, the drugmaker said Wednesday. Leqembi, the company’s closely watched Alzheimer’s medicine, fueled part of the growth.